Health tech startup Carelane sets new standards for clinical research with AI-driven, end-to-end platform
Seed funding of EUR 2.6 million led by Vorwerk Ventures
As clinical studies are always increasing in complexity, research institutions’ software solutions remain fragmented and outdated. Carelane has developed an end-to-end platform that integrates all phases of a study, from protocol development to data analysis. Their innovative approach combines the latest AI technology with a structured digital protocol based on FHIR standards. More than 130 research sites across six continents already rely on Carelane’s software solution. “We’ve engineered a cutting-edge platform that meets the demands of intricate clinical studies and increases efficiency through AI and automation. Workflows are simplified, clinical trials can be completed faster, and the overall quality is elevated,” explains CEO Yannick Boerner.
The research tool of tomorrow
More efficient, cheaper, and higher-quality clinical trials – Carelane achieves this via:
- End-to-end platform: Carelane covers all steps from protocol development to evaluation, with seamless integration promoting efficient collaboration. This eliminates traditional bottlenecks by linking all stakeholders to a shared, real-time infrastructure.
- Resource efficiency: Because there are fewer manual processes, the burden on research sites is eased, leading to cost savings of up to 80 percent. And because of AI-driven assistance and automation, research teams save time on study setup, site onboarding and participant enrolment.
- Increased data quality: Standardized data collection, real-time monitoring with built in AI-agents, and automated validation ensure reliable data and reduce protocol amendments.
A new era for study planning and execution
Carelane supports research teams from the earliest planning phases. The platform’s integrated AI-agents assist in decision-making, planning, and automating complex processes. The structured digital protocol based on FHIR standards ensures improved data quality. It guarantees synchronization with downstream systems and enables source data capture through the ingestion of electronic health records (EHRs). Researchers and study teams can now seamlessly move from creating their digitized protocol to configuring and deploying integrated modules, including EDC, eConsent, eCOA, EHR/EMR integrations, tokenization, and participant management.
Future-proof research – collaborative and integrated
All stakeholders – from sponsors to CROs to research sites – should be able to collaborate in real-time – Carelane makes this a reality. Stakeholders can now manage processes more effectively, and eliminate people silos and data silos. The tool brings all stakeholders together in a single digital infrastructure for the first time. Instead of separate tools, users can now rely on just one platform for medical writing, clinical strategy, operations, and data management. Carelane’s collaborative platform revolutionizes clinical research – a vision that found broad support in the investor community.
Successful seed funding completed
After a successful pre-seed phase, Carelane secured 2.6 million euros in April 2025 during a seed funding round led by Vorwerk Ventures, with additional participation from High-Tech Gründerfonds (HTGF) and private investors. “Carelane is revolutionizing how clinical research is done. We are impressed by how quickly they have gained traction. This rapid adoption shows the value that their AI-driven, end-to-end platform brings to a sector which is hungry for more efficient and higher-quality research. We are excited to support the company in its course of growth,” says Sascha Günther, partner of Vorwerk Ventures. The capital will be used to expand sales and customer support, scale technological infrastructure, and drive the further development of AI functions.
Other news from the department business & finance
